Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Cholinergic Transporters Serve as Potential Targets in Alzheimer’s Disease

Author(s): Renu Bist* and D.K. Bhatt

Volume 24, Issue 4, 2024

Published on: 31 May, 2023

Page: [397 - 398] Pages: 2

DOI: 10.2174/1566524023666230505155302

Price: $65

Abstract

Alzheimer's disease (AD) is a specific brain disease that gradually worsens due to dementia over a long period. AD accounts for almost 60% to 80% of cases of dementia. Any damage to neurons affects their ability to communicate, leading to alteration in thinking, behaviour and feelings. Besides mental, motor abilities of an individual may also be affected due to AD. Therefore, it is cardinal to understand the key mechanisms by which either AD progression can be ceased or, after the onset of the disease it could be reverted. Both of these steps need the identification of a particular receptor or a molecular marker through which a drug can enter the neurons. Cholinergic transporters are such potential targets of AD, which regulate the movement of acetylcholine and thus regulate the nerve impulse conduction in the brain. The current article entails information regarding a variety of cholinergic transporters, which will provide a research gap to the global scientific community.

Next »
[1]
Bist R, Chaudhary B, Bhatt DK. Defensive proclivity of bacoside A and bromelain against oxidative stress and AChE gene expression induced by dichlorvos in the brain of Mus musculus. Sci Rep 2021; 11: 3668.
[2]
Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer’s disease. Molecules 2022; 27(6): 1816.
[3]
Oakley H, Cole SL, Logan S, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26(40): 10129-40.
[4]
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the cholinergic system. Curr Neuropharmacol 2016; 14(1): 101-15.
[5]
Alexander SPH, Kelly E, Marrion N, et al. The concise guide to Pharmacology 2015/16: Transporters. British J Pharmacol 2015; 172: 6110-202.
[6]
Alexander SPH. The concise guide to pharmacology 2021/22: Enzymes. Br J Pharmacol 2021; 178: 313-411.
[7]
Potter LT. Synthesis, storage and release of [14C] acetylcholine in isolated rat diaphragm muscles. J Physiol 1970; 206(1): 145-66.
[8]
Prado VF, Roy A, Kolisnyk B, Gros R, Prado MAM. Regulation of cholinergic activity by the vesicular acetylcholine transporter. Biochem J 2013; 450(2): 265-74.
[9]
Bist R, Bhatt DK. 2010. Augmentation of cholinesterases and ATPase activities in the cerebellum and pons-medulla oblongata, by a combination of antioxidants (resveratrol, ascorbic acid, alpha-lipoic acid and vitamin E), in acutely lindane intoxicated mice. J Neurol Sci 2010; 296(1): 83-7.
[10]
Chaudhary B, Bist R. Protective manifestation of bacoside A and bromelain in terms of cholinesterases, gamma-amino butyric acid, serotonin level and stress proteins in the brain of dichlorvos-intoxicated mice. Cell Stress and Chaperones 2017; 22: 371-6.
[11]
Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci 2005; 6: 48-56.
[12]
Geylis V, Steinitz M. Immunotherapy of Alzheimer’s disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 2006; 5(1): 33-9.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy